Skip Navigation
You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
U.S. Department of Health and Human Services
•
National Institutes of Health
Advanced Search
NIAID Home
Health & Research A to Z
Labs & Scientific Resources
Funding
About NIAID
News & Events
NIAID
>
About NIAID
>
Organization
>
Division of Clinical Research
>
OPOS
>
RCHSPB
Division of Clinical Research
OCSIRF
OPOS
PPAB
RCHSPB
BRB
Skip Website Tools
Website Tools
Email this page
Print this page
Order publications
Skip Stay Connected
Stay Connected
Additional Information From NIAID
DCR Contact Information
Clinical Research Toolkit
Organizational Chart
Javascript Error
Your browser JavaScript is turned off causing certain features of the NIAID Institute of Allergy and Infectious Diseases web site to work incorrectly. Please visit your browser settings and turn JavaScript on.
Read more information on enabling JavaScript.
Regulatory Compliance and Human Subjects Protection Branch (RCHSPB)
Skip Content Marketing
Share this:
The Clinical Trials Management (CTM) Group
Monitors clinical trials to ensure that human subjects are protected, validates the integrity of the data collection and recording process, and ensures compliance with all appropriate regulatory bodies and the ICH/GCP Guidelines. The team consists of a Clinical Research Oversight Manager, a Clinical Trials Manager, a Project Manager, and numerous Clinical Research Associates (CRAs, Monitors).
Provides services such as developing case report forms, protocol study manuals, randomization and treatment allocation codes, and subject study numbers for the investigators in the intramural community and those studies sponsored by the NIAID intramural programs, both domestic and international
Reviews draft protocols, focusing on the "Data Management Plan," "Protocol Monitoring Plan," and "Plan for Use and Storage of Biological Samples" sections of the Protocol as well as on the study procedures, table of events/study schedule, study agent/dosing requirements, and feasibility of procedure implementation, when applicable
Last Updated February 07, 2008